X4 Pharmaceuticals, Inc

X4 Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare immune disorders. Its lead approved product is XOLREMDI (mavorixafor), an oral medicine used in WHIM syndrome, and the company also advances mavorixafor in additional neutropenic and immunology indications.

−1 317,0 %

11,4 %

−1 218,4 %

+150,0 %

10.16

10.16

— X4 Pharmaceuticals, Inc
%
Approved rare-disease therapy55% Commercial sale of XOLREMDI for WHIM syndrome in the U.S. and other approved markets.
License and collaboration revenue40% Upfront, milestone, and license payments from regional commercialization partners.
Manufacturing and supply arrangements5% Drug supply and related commercial manufacturing services under partner agreements.

X4 sells primarily to specialty pharmacy and distribution channels that dispense XOLREMDI to patients prescribed by...

  • Specialty pharmacy channelprimary

    Buys and dispenses approved product to patients after physician prescription; critical for U.S. access.

  • Physicians and rare-disease specialistsprimary

    Prescribe XOLREMDI and drive diagnosis, treatment initiation, and patient follow-up.

  • Third-party payorsprimary

    Reimburse treatment and influence patient access through coverage, rebates, and utilization controls.

  • Regional commercialization partnerssecondary

    License and distribute the product in ex-U.S. territories under local market agreements.

  • Patient advocacy organizationssecondary

    Support disease awareness and early diagnosis, helping expand the treated patient pool.

The company is headquartered in the United States and currently commercializes XOLREMDI in the U.S...

  • •United States is the core commercial market for XOLREMDI
  • •U.S. distribution runs through specialty pharmacy and logistics partners
  • •Europe is targeted through a licensing deal with Norgine
  • •MENA commercialization is handled through taiba rare in select countries
  • •Additional ex-U.S. markets may be added where approvals can be leveraged

X4’s strategy centers on building the commercial footprint of XOLREMDI while expanding the addressable market for...

01
Grow U.S. commercial uptake of XOLREMDIshort-term

The approved product is the main near-term revenue engine and depends on diagnosis and access.

02
Expand ex-U.S. commercialization through partnersmedium-term

Licensing reduces the need for direct international infrastructure while broadening market reach.

03
Broaden the mavorixafor franchise beyond WHIM syndromemedium-term

Additional indications can enlarge the patient pool and diversify dependence on one rare disease.

X4 is exposed to the risks typical of a small commercial-stage biotech: dependence on a single approved product,...

high

Product concentration

A large share of value depends on XOLREMDI and mavorixafor-related programs.

Scope
Single approved product and one core molecule
Materiality
high
high

Need for additional capital

Commercial launch and clinical development consume cash before sustained profitability.

Scope
Equity, debt, partnerships, and strategic funding
Materiality
high
high

Supply chain concentration

The company relies on single-source suppliers for active drug and finished capsules.

Scope
Manufacturing and commercial supply
Materiality
high
high

Clinical and development execution

Future growth depends on successful trials and regulatory approvals in new indications.

Scope
Phase 3 and other development programs
Materiality
high
medium

Regulatory and healthcare compliance

Pricing, rebates, patient support, and promotion are constrained by healthcare laws.

Scope
U.S. and foreign commercialization
Materiality
medium
Revenue recognition for collaboration and license agreements
Can create lumpy quarterly revenue and timing differences
Net product revenue reserves
Affects gross-to-net deductions and comparability across periods
Royalty and sublicense accounting
Influences reported product margin and operating leverage
Intangible asset and milestone amortization
Can materially affect gross profit presentation

C4 Therapeutics, Inc.

CCCC · Biological Products, (No Diagnostic Substances)

XBiotech Inc.

XBIT · Pharmaceutical Preparations

4D Molecular Therapeutics, Inc.

FDMT · Biological Products, (No Diagnostic Substances)

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

Xilio Therapeutics, Inc.

XLO · Pharmaceutical Preparations

: 29.4.2026